H Mathijssen M P Huitema A L M Bakker J J Mager R J Snijder J C Grutters M C Post
10.36141/svdld.v37i1.9292
Sarcoidosis Vasc Diffuse Lung Dis
2020;37(1):74-78.
endothelin receptor antagonist macitentan pulmonary hypertension sarcoidosis
CC BY-NC-SA
https://pubmed.ncbi.nlm.nih.gov/33093771/
Antihypertensive Agents / therapeutic use Arterial Pressure / drug effects Endothelin Receptor Antagonists / therapeutic use Hypertension, Pulmonary / drug therapy Pulmonary Artery / drug effects Pyrimidines / therapeutic use Sarcoidosis, Pulmonary / complications Sulfonamides / therapeutic use
Antihypertensive Agents / therapeutic use Arterial Pressure / drug effects Endothelin Receptor Antagonists / therapeutic use Hypertension, Pulmonary / drug therapy Pulmonary Artery / drug effects Pyrimidines / therapeutic use Sarcoidosis, Pulmonary / complications Sulfonamides / therapeutic use Case Reports Aged Antihypertensive Agents / adverse effects Databases, Factual Endothelin Receptor Antagonists / adverse effects Exercise Tolerance / drug effects Female Humans Hypertension, Pulmonary / diagnosis Hypertension, Pulmonary / etiology Hypertension, Pulmonary / physiopathology Male Middle Aged Pulmonary Artery / physiopathology Recovery of Function Retrospective Studies Sarcoidosis, Pulmonary / diagnosis Time Factors Treatment Outcome Antihypertensive Agents Endothelin Receptor Antagonists Pyrimidines Sulfonamides macitentan
PMC7569544
33093771
Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-series
2020